

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 2023

---

Commission File Number: 001-38723

---

**Tiziana Life Sciences LTD**

(Exact Name of Registrant as Specified in Its Charter)

---

9<sup>th</sup> Floor  
107 Cheapside  
London  
EC2V 6DN

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On May 17, 2023, Tiziana Life Sciences LTD (the "Company") issued a press release, announcing Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TIZIANA LIFE SCIENCES LTD**

Date: May 17, 2023

By: /s/ Keeren Shah

Name: Keeren Shah

Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	<a href="#">News Service Announcement, dated May 17, 2023</a>



# Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

NEW YORK, May 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLISA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer, is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 16 in San Diego.

“I was truly honored when Hanson Wade contacted me requesting that I speak at its Novel Nasal Formulation and Delivery Summit<sup>1</sup>,” stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. “I will be joined at the summit by several distinguished speakers from the industry and the FDA.<sup>2</sup> The continued interest we receive on our intranasal foralumab program from pharma, investors and the media demonstrates that our novel approach to deliver the only fully human anti-CD3 monoclonal antibody intranasally has captured the attention of the medical community.”

## About Foralumab

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<sup>3</sup>

## About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

## Tiziana Life Sciences Ltd

Paul Spencer, Business Development and Investor Relations  
+44 (0) 207 495 2379  
email: [info@tizianalifesciences.com](mailto:info@tizianalifesciences.com)

## Investors:

Irina Koffler  
LifeSci Advisors, LLC  
+1 646 970 4681  
[ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)

<sup>1</sup> <https://www.nasal-formulation-delivery.com/>

<sup>2</sup> <https://www.nasal-formulation-delivery.com/whats-on/speakers/>

<sup>3</sup> <https://www.pnas.org/doi/10.1073/pnas.2220272120>